This is a working overview of circadian clock, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-09. Anything still debated is marked as such rather than presented as settled.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
In the coastal areas of the southeast (such as Florida, the Carolinas and Louisiana), bears inhabit a mixture of flatwoods, bays and swampy hardwood sites. In the northeastern part of the range (the United States and Canada), prime habitat consists of a forest canopy of hardwoods such as beech, maple, birch and coniferous species. Corn crops and oak-hickory mast are also common sources of food in some sections of the northeast; small, thick swampy areas provide excellent refuge cover largely in stands of white cedar. Along the Pacific coast, redwood, Sitka spruce and hemlocks predominate as overstory cover. Within these northern forest types are early successional areas important for American black bears, such as fields of brush, wet and dry meadows, high tidelands, riparian areas and a variety of mast-producing hardwood species. The spruce-fir forest dominates much of the range of the American black bear in the Rockies. Important non-forested areas here are wet meadows, riparian areas, avalanche chutes, roadsides, burns, sidehill parks and subalpine ridgetops. In areas where human development is relatively low, such as stretches of Canada and Alaska, American black bears tend to be found more regularly in lowland regions. In parts of eastern Canada, especially Labrador, American black bears have adapted exclusively to semi-open areas that are more typical habitat in North America for brown bears (likely due to the absence there of brown and polar bears, as well as other large carnivore species).
Commonly used salts in lysing buffers include: a. Sodium chloride (NaCl): NaCl is often included to maintain isotonic conditions, preventing osmotic shock and cell rupture during the lysis process. b. Potassium chloride (KCl): Similar to NaCl, KCl can be used to adjust the ionic strength and facilitate cell lysis. Enzymes: Certain enzymes are added to lysing buffers to enhance cell lysis by digesting specific cellular components that can interfere with the extraction of the target enzyme. Examples of enzymes used in lysing buffers include: a. Lysozyme: Lysozyme breaks down the peptidoglycan layer of bacterial cell walls, weakening their structural integrity and facilitating subsequent disruption. It is particularly effective for Gram-positive bacteria. b. DNase (Deoxyribonuclease): DNase degrades DNA present in the lysate, reducing its viscosity and preventing DNA-related interference in downstream purification steps. c. RNase (Ribonuclease): Similar to DNase, RNase degrades RNA in the lysate, reducing its viscosity and minimizing RNA-related interference. The specific combination and concentrations of detergents, salts, and enzymes in lysing buffers can vary depending on the target enzyme, cell type, and experimental requirements, optimization of these components is crucial to achieve efficient cell lysis while preserving the stability and activity of the desired enzyme during the purification process.
=== Interactions with Solvent === Increasing addition of solute will alter the solvent's viscosity and polarizability, which cannot be measured by instruments that rely on low viscosity. Since differential refractometer is an external tool, the solvent viscosity does not pose a physical barrier to measurement, making them universal detectors.
Sources: en.wikipedia.org
Doxylamine is used medically as doxylamine succinate, the succinate salt of doxylamine, and is available both alone (brand names Decapryn, Doxy-Sleep-Aid, Unisom) and in combination with pyridoxine (a form of vitamin B6) (brand names Bendectin, Bonjesta, Diclegis). Doxylamine is available alone as immediate-release oral tablets containing 25 mg doxylamine succinate. Oral tablets containing 12.5 mg doxylamine succinate as well as oral capsules containing 25 mg doxylamine succinate were also previously available but were discontinued. The combination of doxylamine and pyridoxine is available in the form of extended- and delayed-release oral tablets containing 10 to 20 mg doxylamine succinate and 10 to 20 mg pyridoxine hydrochloride. Doxylamine alone is available over-the-counter, whereas doxylamine in combination with pyridoxine is a prescription-only medication. Doxylamine is also available in over-the-counter nighttime cold medicine products such as NyQuil Cold & Flu (contains acetaminophen, doxylamine succinate 6.25 to 12.5 mg, and dextromethorphan hydrobromide), where it is the sedating component.
9 January – Séamus Begley, 73, traditional musician and singer. 16 January Carrie Acheson, 88, politician, TD (1981–1982). Joe Martin, 91, footballer (Dundalk, League of Ireland XI). 18 January – John L. Murray, 79, jurist, chief justice (2004–2011), judge of the Supreme Court (1999–2015) and the ECJ (1992–1999). 19 January Bertie Cunningham, 83, Gaelic footballer (Ballivor, Meath senior team). Peter Thomas, 78, footballer (Waterford, Galway United, national team). Born in England. 20 January – Pierce Higgins, 45, hurler (Tooreen, Ballyhaunis, Mayo senior team), motor neuron disease. 21 January – Micheál Mac Gréil, 91, Jesuit priest, sociologist and writer. 30 January – Eddie Spence, 97, Gaelic footballer (Belfast O'Connell's, Antrim senior team). Born in Northern Ireland. 31 January – Donie Hanlon, 85, Gaelic footballer (Gracefield, Offaly senior team).
=== Water filtration === Given the water adsorption properties of silica gel, it is used in domestic water filters. The surface structure of silica gel allows the adsorption of some minerals that are dissolved in the water, or "ion exchange" as it is marketed. Due to the lack of regulations for domestic water filtration products, no studies validate the manufacturer claims regarding the effectiveness of the filtration system.
==== Germany ==== The Federal Office for Radiation Protection has developed a radon map of Germany. The EU Directive 2013/59/Euratom (Radiation Protection Basic Standards Directive) introduced reference levels and the possibility for workers to have their workplace tested for radon exposure. In Germany, it was implemented in the Radiation Protection Act (Chapter 2 or Sections 124-132 StrlSchG) § 124-132 StrlSchG (in German) and the amended Radiation Protection Ordinance (Part 4 Chapter 1, Sections 153-158 StrlSchV). § 153-158 Act of (in German) The new radon protection regulations for workplaces and new residential buildings have been binding since January 2019. Extensive radon contamination and radon precautionary areas have been determined by the ministries of the environment of the federal states (as of June 15, 2021).
Sources: en.wikipedia.org
==== Dopaminergic pathway and reward suppression ==== The mesolimbic dopaminergic circuit functions as a substrate for KOR-regulated mood homeostasis. Dynorphin is synthesized and released by dopamine D1 receptor-expressing medium spiny neurons within the NAcc, establishing a local negative feedback loop that suppresses dopamine release. KOR activation on dopamine terminals inhibits dopamine release through multiple mechanisms: increased potassium conductance via G protein-coupled inward-rectifier potassium (GIRK) channels, suppression of calcium entry, activation of protein kinase C-β (PKCβ), c-Jun N-terminal kinase (JNK), and ERK, as well as facilitation of dopamine transporter (DAT) function through ERK1/2-dependent pathways that accelerate dopamine reuptake. Additionally, KOR activation on local dynorphin-expressing neurons produces presynaptic inhibition of both glutamatergic and GABAergic afferents onto D1 receptor-expressing medium spiny neurons, with preferential suppression of amygdala inputs to D1-MSNs while facilitating integration of hippocampal/amygdalar inputs onto D2 receptor-expressing neurons through disinhibition. In the caudal NAcc shell, KOR-induced dopamine suppression triggers anxiogenic behaviors accompanied by reduced locomotor activity. Conversely, in the rostral shell, KOR activation produces attenuated dopaminergic suppression with diminished aversive behavioral consequences.
6,14-Endoethenotetrahydrooripavine is the central nucleus, or backbone, of a class of morphinan opioids known as the Bentley compounds and may be considered their "privileged scaffold". These include but are not limited to etorphine and buprenorphine. They usually have thebaine or oripavine as their precursor in their syntheses (and are thus termed "thevinols" and "orvinols", respectively).
Benfluorex (removed from the market by the EMA due to increased risk of heart disease) Butenolide Diethylpropion FG-7142 Phenmetrazine† (withdrawn in some countries due to the danger of addiction) Phentermine Phenylpropanolamine Pyroglutamyl-histidyl-glycine Sibutramine Other compounds with known appetite suppressant activity include:
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.